Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab mechanistic study in COPD among former and current smokers
NL-OMON60140Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of itepekimab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Sanofi. Primary endpoints: Change from baseline in itepekimab pharmacodynamic normalized enrichment score in endobronchial biopsies, Change from baseline in itepekimab pharmacodynamic normalized enrichment score in bronchial brushings and 1 more. Started Nov 2022; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON60140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60140.